NEW YORK, July 9, 2015 /PRNewswire/ — Small Cap IR issues report: PharmaCyte Biotech, Inc. (OTCQB: PMCB) “Cell-in-a-Box” platform exhibits significant potential. Any cell type could potentially be implanted in the body without need for administration of any drugs that decrease the body’s immune response. This is important for potential therapies and will dramatically increase versatility and value of this technology into the future. The PMCB platform is a cellulose based “bead” containing live cells. The porous nature of the beads allowed nutrients to enter and support the health of the encapsulated cells. In addition, beads are porous enough to permit activated drugs or other biological substances to leave and provide benefit to their surrounding environment.
This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, diabetes and delivery of cannabis based treatments are being built.
For a brief report with analyst comments and recommendation on PMCB please follow the link. There is no cost obligation required to view report.
Copy and paste to browser may be required.
About Small Cap IR
We make the connection between sophisticated investors and high quality small cap companies. An issuer of reports written research analysts who provide an opinion of the profiled company. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges. For more information and services provided beyond this release please use contact information provided below.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and may make mistakes. If you notice any errors or omissions, please notify us below. A full disclaimer can be found by viewing the analyst report.
SOURCE Small Cap IR